2024-10-24 - Analysis Report
## Amgen Inc. (AMGN) Stock Analysis Report

**Company Overview:** Amgen Inc. is a leading biotechnology company that develops and markets pharmaceuticals for various diseases.

**1. Performance Comparison:**

* **Cumulative return:** AMGN: 76.54%, VOO: 136.39%
* **Return difference:** -59.85%
* **Relative divergence:** 26.31% (This indicates that AMGN's performance is currently in the 26.31st percentile compared to its historical range relative to VOO.)

**2. Recent Price Action:**

* **Closing price:** $315.68
* **5-day moving average:** $319.41
* **20-day moving average:** $320.64
* **60-day moving average:** $325.96

**3. Technical Indicators:**

* **RSI:** 44.15 (Neutral; suggests neither overbought nor oversold condition)
* **PPO:** -0.12 (Slightly bearish; suggests a potential downside momentum)
* **Delta_Previous_Relative_Divergence:** -12.87 (Short-term bearish; indicates a recent relative weakness)
* **Expected_Return:** 0.0% (Long-term expected return against S&P 500)

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-07 | 1.39 | 8.39 B$ |
| 2024-05-03 | -0.21 | 7.45 B$ |
| 2023-10-31 | 3.23 | 6.90 B$ |
| 2023-08-04 | 2.58 | 6.99 B$ |
| 2024-08-07 | 2.58 | 6.99 B$ |

* **Recent Earnings (2024-08-07):** The company reported EPS of $1.39, exceeding analyst expectations of $1.35. Revenue of $8.39B also surpassed analyst expectations of $8.31B.

**5. News and Recent Issues:**

* **Recent Market Outlook:** FINBOLD reports that Amgen's stock has been underperforming the market this year due to concerns about its drug pipeline and competition in the biopharmaceutical industry. However, the company has shown resilience and is expected to see growth in the coming years, driven by its established drug portfolio.
* **Analyst Opinions:**  Most analysts are optimistic about Amgen's future prospects and have a "buy" or "hold" rating on the stock.
* **Performance Highlights:** Amgen has been consistently delivering strong financial performance, with consistent revenue growth and a robust portfolio of products.

**6. Comprehensive Analysis:**

Amgen Inc. (AMGN) is a leading biotechnology company with a strong track record of profitability and a diverse portfolio of drugs. However, the stock has underperformed the market in recent months due to concerns about its drug pipeline and competition. While the company has shown resilience and is expected to see growth in the coming years, its current price performance lags behind the broader market. Technical indicators suggest potential weakness in the short term, but the long-term outlook remains positive, particularly with the company's consistent financial performance and strong product portfolio.

**7. Overall Conclusion:**

Despite the recent underperformance, AMGN remains a strong company with solid financials and a promising future. However, investors should be aware of the current market sentiment and monitor the company's progress in addressing the challenges it faces. The long-term growth potential remains intact, and investors seeking a stable and profitable company in the biotechnology sector may find AMGN to be a good investment. 
